findmyKOL

Seema Harichand-Herdt, MD

Basic profile

Iowa Oncology Research Association

ORCIDNone on fileNPI
RegionDes Moines, IA · MidwestSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Seema Harichand-Herdt is an Oncology physician affiliated with Iowa Oncology Research Association. OpenAlex indexes 16 publications with 337 citations (h-index 6).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
16publications

Distinct works indexed by OpenAlex.

337citations

Total citations across indexed works.

6h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
5companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

411 Laurel St Ste A300
Des Moines, IA 503143030

Telephone

515-282-2921

Provider last certified this registry record 18 Nov 2025.

View the NPPES registry record

Industry payments

5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    40.3%
    Aromatase Inhibitor25.2%
    Anastrozole79%Letrozole18%Exemestane3%
    Part D<11 patients
    Thalidomide Analog5.2%
    Lenalidomide78%Revlimid22%
    Part D<11 patients

    + 5 more classes in this area

  • Nervous system

    25%
    Atypical Antipsychotic6.6%
    Olanzapine100%
    Part D37 patients
    Gabapentinoids5.2%
    Gabapentin100%
    Part D22 patients

    + 4 more classes in this area

  • Metabolism & gastrointestinal

    14.6%
    Serotonin-3 Receptor Antagonist4.5%
    Ondansetron Hcl80%Ondansetron Odt21%
    Part D<11 patients
    Potassium supplement3.1%
    Potassium Chloride100%
    Part D21 patients

    + 4 more classes in this area

Where care is delivered (Part B)5.9% facility · 94.1% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”